NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
40 hedge funds and large institutions have $3.85M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
90% less call options, than puts
Call options by funds: $6K | Put options by funds: $60K
Holders
40
Holding in Top 10
–
Calls
$6K
Puts
$60K
Top Buyers
| 1 | +$435K | |
| 2 | +$293K | |
| 3 | +$135K | |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$50.6K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$34K |
Top Sellers
| 1 | -$306K | |
| 2 | -$88K | |
| 3 | -$66K | |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$41K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$38K |